ANKE BIO(300009)2024-10-24 10:02Financial Performance - The company's revenue for Q3 2024 was ¥622,465,100.14, a decrease of 15.21% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥173,587,269.81, down 32.73% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥165,223,107.41, a decline of 33.27% compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 1,921,280,101.12, a decrease of 4.95% compared to CNY 2,021,384,056.69 in the same period last year[17] - The net profit for Q3 2024 was CNY 599,915,131.57, a decrease of 9.7% compared to CNY 664,620,477.53 in Q3 2023[18] - The total profit for Q3 2024 was CNY 698,275,336.46, down from CNY 767,775,513.10 in Q3 2023, reflecting a decrease of 9.0%[18] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.35, down from CNY 0.39 in the same period last year[19] Cash Flow and Liquidity - The company's cash flow from operating activities for the year-to-date was ¥420,904,489.18, down 32.74% year-on-year[2] - The net cash flow from operating activities decreased by 32.74% to ¥420,904,489.18 compared to ¥625,829,554.66 in the same period last year, primarily due to significant employee compensation payments and increased market investments[8] - The company reported an increase in cash received from other operating activities to CNY 23,206,682.80, compared to CNY 7,564,584.45 in the same period last year[20] - The company's cash and cash equivalents increased to approximately ¥353.13 million from ¥260.23 million, reflecting a growth of 35.7%[14] - The total cash and cash equivalents at the end of Q3 2024 amounted to CNY 350,781,357.61, up from CNY 244,122,328.46 at the end of Q3 2023[21] - The company's financing activities resulted in a net cash outflow of CNY 444,876,950.15, compared to a net outflow of CNY 405,805,654.59 in Q3 2023[21] Assets and Liabilities - Total assets at the end of Q3 2024 reached ¥4,990,978,472.71, reflecting a slight increase of 0.81% from the end of the previous year[2] - The company's total current assets decreased to approximately ¥2.24 billion from ¥2.33 billion, a decline of 3.1%[14] - The company's total assets decreased to approximately ¥2.24 billion from ¥2.33 billion, a decline of 3.8%[14] - The company’s total liabilities decreased to approximately ¥1.12 billion from ¥1.15 billion, a decline of 2.6%[14] - Non-current liabilities decreased to CNY 158,813,455.35 from CNY 171,347,690.88, reflecting a reduction of 7.27%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 66,605, with the top ten shareholders holding a significant portion of the shares[9] - Song Lihua, the actual controller of the company, holds 26.50% of the shares, amounting to 444,278,710 shares[9] - The second-largest shareholder, Song Liming, holds 6.85% of the shares, totaling 114,889,420 shares[9] - The top ten shareholders include various institutional investors, with the largest institutional shareholder holding 1.84% of the shares[9] - The company has not disclosed any related party relationships among the top shareholders, except for the relationship between Song Lihua and Song Liming, who are brothers[10] - The company has not engaged in any share lending activities among the top ten shareholders during the reporting period[10] Investment and Development - The company completed the acquisition of a 3.3480% stake in Anhui Xinhua Kun Biotechnology Co., increasing its ownership from 58.55% to 61.90%[13] - The company’s investment in debt securities increased to approximately ¥176.54 million from ¥72.16 million, a significant increase of 144.5%[14] - Research and development expenses were CNY 128,568,208.02, down 16.00% from CNY 152,939,567.06 in the previous year[17] - The company is focusing on enhancing its data resources and intangible assets, with development expenditures rising to CNY 225,991,101.14, up from CNY 215,952,222.05[16] - Future outlook includes continued focus on market expansion and potential new product development initiatives[8] - The company plans to expand its market presence and invest in new product development to drive future growth[17] Income and Expenses - Total operating costs increased to CNY 1,268,341,322.03, up 0.47% from CNY 1,257,752,219.43 year-on-year[17] - The company reported a net profit margin improvement, with net profit for the period showing a positive trend due to cost management strategies[17] - The company experienced a 2230.90% increase in non-operating income, amounting to ¥712,568.27, due to the settlement of previously unpaid liabilities[7] - Other income increased by 151.02% to ¥29,164,487.19, primarily due to higher government subsidies received[6] - Investment income surged by 598.85% to ¥14,703,993.65, attributed to substantial returns from financial products and large certificates of deposit[6]